JNJ-26481585 is primarily investigated for its potential in cancer therapy, particularly as a histone deacetylase (HDAC) inhibitor. It is studied for its ability to induce apoptosis and inhibit the proliferation of cancer cells by modifying gene expression. This compound has shown promise in preclinical studies for treating various types of cancers, including hematological malignancies and solid tumors. It has advanced to clinical trials to further assess its safety, efficacy, and potential in humans. Researchers are exploring its efficacy in combination with other anticancer agents to enhance therapeutic outcomes. Its role in epigenetic regulation makes it a valuable candidate for targeted cancer treatments.